Related Experiment Video
Updated: Apr 12, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Spatial genomic heterogeneity within localized, multifocal prostate cancer
Paul C Boutros1, Michael Fraser2, Nicholas J Harding3
11] Ontario Institute for Cancer Research, Toronto, Ontario, Canada. [2] Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada. [3] Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Abstract:
Herein we provide a detailed molecular analysis of the spatial heterogeneity of clinically localized, multifocal prostate cancer to delineate new oncogenes or tumor suppressors. We initially determined the copy number aberration (CNA) profiles of 74 patients with index tumors of Gleason score 7. Of these, 5 patients were subjected to whole-genome sequencing using DNA quantities achievable in diagnostic biopsies, with detailed spatial sampling of 23 distinct tumor regions to assess intraprostatic heterogeneity in focal genomics. Multifocal tumors are highly heterogeneous for single-nucleotide variants (SNVs), CNAs and genomic rearrangements. We identified and validated a new recurrent amplification of MYCL, which is associated with TP53 deletion and unique profiles of DNA damage and transcriptional dysregulation. Moreover, we demonstrate divergent tumor evolution in multifocal cancer and, in some cases, tumors of independent clonal origin. These data represent the first systematic relation of intraprostatic genomic heterogeneity to predicted clinical outcome and inform the development of novel biomarkers that reflect individual prognosis.
Insights
This study reveals significant genomic differences within multifocal prostate tumors, identifying MYCL amplification as a key factor. These findings highlight tumor evolution and can aid in developing new prognostic biomarkers.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Prostate cancer exhibits multifocality and spatial heterogeneity.
- Understanding intraprostatic genomic variation is crucial for targeted therapies and prognosis.
Purpose of the Study:
- To perform a detailed molecular analysis of spatial heterogeneity in clinically localized, multifocal prostate cancer.
- To identify novel oncogenes or tumor suppressors contributing to prostate cancer progression.
Main Methods:
- Copy number aberration (CNA) profiling of 74 patients with Gleason score 7 index tumors.
- Whole-genome sequencing of 23 distinct tumor regions from 5 patients to assess focal genomics.
- Analysis of single-nucleotide variants (SNVs), CNAs, and genomic rearrangements.
Main Results:
- Multifocal prostate tumors display significant heterogeneity in SNVs, CNAs, and genomic rearrangements.
- A recurrent amplification of MYCL was identified, associated with TP53 deletion.
- Evidence of divergent tumor evolution and independent clonal origins was observed.
Conclusions:
- Intraprostatic genomic heterogeneity is a key feature of multifocal prostate cancer.
- MYCL amplification and TP53 deletion are significant molecular events.
- Genomic data can inform the development of prognostic biomarkers for personalized treatment.
